EVALUATION OF CARBOPLATIN AS A SINGLE-AGENT IN HIGHLY REFRACTORY ACUTE MYELOID-LEUKEMIA

Thirteen patients (pts) with highly refractory acute myeloid leukemia (AML) 10 pts with de novo AML and 3 with blast crisis of chronic myelo id leukemia were treated with carboplatin (CP) 150 mg/m(2)/day through continuous IV infusion for 7 consecutive days. Seven of them received CP at least as third or more line therapy after a median duration of the disease of 26 weeks. None achieved a complete remission but a good hematologic response, with disappearance of circulating blast cells a long with correction of bone marrow failure, persisting for 3 months w as obtained in one patient and correction of hyperbasophilemia was obs erved in another with blast crisis of chronic myelogenous. Myelosuppre ssion was the most consistent toxic effect. Two deaths occurred, one f rom renal acute failure and the other from sepsis. Median survival aft er CP was 8 weeks (range 4 days-11 months) and the majority of patient s were able to return home. When used as a single agent and with the d ose-schedule used in this study, CP does not appear effective in refra ctory AML. Other studies are necessary